<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595255</url>
  </required_header>
  <id_info>
    <org_study_id>CHANCE (CHildren, Amh, caNCEr)</org_study_id>
    <nct_id>NCT02595255</nct_id>
  </id_info>
  <brief_title>AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)</brief_title>
  <acronym>CHANCE</acronym>
  <official_title>Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While most of the children spontaneously recover menstruation or experienced normal puberty
      after chemotherapy, their ovarian reserve may be impaired by treatment inducing future
      infertility. Fertility preservation is currently proposed for selected prepubertal patients
      with a high risk of premature ovarian failure after treatment (mostly conditioning regimen
      for bone marrow transplantation). For patients with low or moderate risks, counselling is
      very difficult and no fertility preservation procedure is usually proposed for these patients
      as no marker of the ovarian reserve has been validated in this young population to assess the
      individual risk.

      The primary objective of the study is to prevent long-term treatment-related infertility by
      detecting the young patients who normally progressed to menarche but have a reduced ovarian
      reserve. These patients may benefit from particular follow-up and fertility preservation
      procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, we will prospectively evaluate the AMH level before and after
      treatment (up to 18 years old) in a large cohort of pre- and post-pubertal children treated
      for cancer. The children enrolled are young patients between 3 and 14 year old who are newly
      diagnosed with cancer or benign diseases treated by chemotherapy and/or pelvic irradiation.
      They belong to one of these 3 groups (modified from Wallace et al, 2005):

        -  High risk

        -  Moderate/Low risk

        -  No risk (control group)

      Primary endpoint:

      Evaluate AMH as a potential biomarker of ovarian reserve in prepubertal/pubertal girl treated
      by chemotherapy (classified according to the AAD score)

      Secondary endpoints:

        -  Evaluate the association between the post-treatment ovarian reserve and the AMH
           pretreatment values in patients considered as moderate or low risk.

        -  Identify new patients group who may benefit from fertility preservation

        -  Compare the gonadotoxicity of chemotherapy regimen according to the pubertal status.

        -  Study the relation between the AMH levels and the pubertal age, menstruation cycle
           regularity, hormonal levels (FSH, œstradiol, and testosterone) and bone age.

      Different parameters will be assessed at inclusion, end of the treatment and during the
      follow-up (every year during the first 3 years and then every 2 years until the end of the
      study) Oncological outcome The patients will be followed up for progression and survival as
      per standard local practice.

      Ovarian reserve and function:

      Ovarian reserve will be evaluated based on hormonal dosages at different times of the study:
      FSH, AMH, estradiol, testosterone and LH. Menstrual function will be evaluated by collecting
      information of the pubertal status (spontaneous or induced puberty) and menstrual cycle
      characteristics

      Puberty evaluation:

      All children will have an evaluation of the TANNER pubertal stage at 9 years of age (or later
      if &gt; 9 years old at the time of inclusion) and once a year until the end of puberty (when
      patients reach Tanner stage 5). An X-ray of the left hand and wrist will be carried out for
      bone age evaluation at 9-11 and 13 years old.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">December 2035</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AMH marker</measure>
    <time_frame>screening, 1 year after screening, every year during the first 3 year of follow-up, every 2 years until 18 year old</time_frame>
    <description>Blood test collection for serum storage. AMH values will be compared in the different groups and correlated with the cumulative doses of alkylating agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Premature ovarian failure (POF)</measure>
    <time_frame>screening, 1 year after screening, every year during the first 3 year of follow-up, every 2 years until 18 year old</time_frame>
    <description>Blood test collection for serum storage. FSH, E2 and AMH measurement and pubertal status. POF rate will be compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian reserve</measure>
    <time_frame>screening, 1 year after screening, every year during the first 3 year of follow-up, every 2 years until 18 year old</time_frame>
    <description>relation between the AMH levels, pubertal age, menstruation cycle regularity, hormonal levels (FSH, œstradiol, and testosterone at 16 year old) and bone age</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Fertility Preservation</condition>
  <condition>Lymphoma</condition>
  <condition>Pediatrics Cancer</condition>
  <condition>Gonadotropin-releasing Hormone Agonist</condition>
  <arm_group>
    <arm_group_label>High risk</arm_group_label>
    <description>Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate/low risk</arm_group_label>
    <description>Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.
This is the study group we will compare with high risk and no risk patients. No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No risk</arm_group_label>
    <description>Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.
No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>High risk</arm_group_label>
    <arm_group_label>Moderate/low risk</arm_group_label>
    <arm_group_label>No risk</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum for hormonal assessment
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population for this trial is patients between 3 and 14 year old newly diagnosed with
        cancer or benign diseases treated by chemotherapy and/or pelvic irradiation with high or
        moderate risk of inducing premature ovarian insufficiency. The &quot;no risk&quot; group includes
        patients with chronic benign diseases (as pneumology or gastroenterology diseases,
        congenital hypothyroidism, growth hormone deficiency or RCIU…) or malignancies who will not
        receive any chemotherapy or other gonadotoxic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified
             from Wallace et al, 2005):

               -  High risk : Conditioning therapy for bone marrow transplantation or pelvic
                  irradiation

               -  Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate
                  or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing
                  sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue
                  sarcoma, ALL, Wilms tumour, retinoblastoma.

               -  No risk (control group) : patients with chronic benign diseases or malignancies
                  who don't receive any chemotherapy or other gonadotoxic treatment.

        Exclusion Criteria:

          -  CNS irradiation, cerebral tumour

          -  Current or previous ovarian disease/surgery

          -  Familial history of premature ovarian failure (no iatrogenic or surgical origins)

          -  Previous known severe chronic disease potentially affecting normal growth or puberty
             (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner,
             Kallman, BPES syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune
             diseases, cystic fibrosis, severe renal dysfunction)

          -  Genetic/congenital disorders inducing mental retardation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Demeestere, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Erasme ULB- Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alina Ferster</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Fabiola children's university hospital- Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Decanter</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Demeestere, PhD</last_name>
    <phone>+32 2 555 65 92</phone>
    <email>idemeest@ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Dechene</last_name>
    <phone>+32 2 555 63 58</phone>
    <email>jdechene@ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance</name>
      <address>
        <city>Montegnée</city>
        <state>Liège</state>
        <zip>4420</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Collin</last_name>
      <phone>+32 4 224 91 42</phone>
      <email>morgan.collin@chc.be</email>
    </contact>
    <investigator>
      <last_name>Nadine Francotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Anvers</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Ryckaert</last_name>
      <phone>+32 3 821 58 39</phone>
      <email>hanna.ryckaert@uza.be</email>
    </contact>
    <investigator>
      <last_name>Joris Verlooy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Reine Fabiola (HUDERF)</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merry Vanpuyvelde</last_name>
      <phone>+32 2 477 38 85</phone>
      <email>merry.vanpuyvelde@huderf.be</email>
    </contact>
    <contact_backup>
      <last_name>Bernard Wenderickx</last_name>
      <phone>+32 2 477 36 54</phone>
      <email>bernard.wenderickx@huderf.be</email>
    </contact_backup>
    <investigator>
      <last_name>Alina Ferster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiert Robberechts</last_name>
      <phone>+32 2 801 28 14</phone>
      <email>Wiert.Robberechts@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Jutte Van der Werff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ-Gent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Els Vandecruys</last_name>
      <email>Els.Vandecruys@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Els Vandecruys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jemima Gaytant</last_name>
      <phone>+32 16 34 37 63</phone>
      <email>jemima.gaytant@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Anne Uyttebroeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional (CHR)-Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Sondag</last_name>
      <phone>+32 4 321 89 77</phone>
      <email>Catherine.Sondag@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Caroline Piette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vandermeersch</last_name>
      <phone>+33 3 20 29 58 26</phone>
      <email>s-vandermeersch@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène Sudour-Bonnange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille-Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Veron</last_name>
      <phone>+33 3 20 44 60 58</phone>
      <email>cecile.veron@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Benedicte Bruno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Hugue Dalle</last_name>
      <email>jean-hugues.dalle@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean- Hugue Dalle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012 Jun;97(6):2059-67. doi: 10.1210/jc.2011-3180. Epub 2012 Apr 3.</citation>
    <PMID>22472563</PMID>
  </reference>
  <reference>
    <citation>Wallace WH, Smith AG, Kelsey TW, Edgar AE, Anderson RA. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol. 2014 Sep;15(10):1129-36. doi: 10.1016/S1470-2045(14)70334-1. Epub 2014 Aug 14.</citation>
    <PMID>25130994</PMID>
  </reference>
  <reference>
    <citation>Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, Delbaere A, Devreker F, Ferster A. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015 Sep;30(9):2107-9. doi: 10.1093/humrep/dev128. Epub 2015 Jun 9.</citation>
    <PMID>26062556</PMID>
  </reference>
  <reference>
    <citation>Imbert R, Moffa F, Tsepelidis S, Simon P, Delbaere A, Devreker F, Dechene J, Ferster A, Veys I, Fastrez M, Englert Y, Demeestere I. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis. Hum Reprod. 2014 Sep;29(9):1931-40. doi: 10.1093/humrep/deu158. Epub 2014 Jun 22.</citation>
    <PMID>24958067</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy/GnRH analogues/lymphoma/children/fertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

